Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Suzhou's Innovent Rises 19% in First Trading Day on the Hong Kong Exchange

publication date: Oct 31, 2018

Suzhou's Innovent Biologics climbed 19% higher in its first day of trading on the Hong Kong Exchange, following its IPO last week. The positive reception is the first time investors have driven one of Hong Kong's pre-revenue biopharma IPOs higher in open market trading. Although the anticipation for the pre-revenue channel was very high, the previous three listings closed their first sessions more of less unchanged -- and then moved lower in subsequent days, causing investors to wonder if Hong Kong's channel for young biopharmas is a viable vehicle. Innovent's performance creates hope that it is. More details....

Stock Symbol: (HK: 1801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.